



2021 Virtual Congress – Scientific Program

All program timing in CEST

| | |
|---|---|
| Pre-Congress, Thursday, May 6th | |
| 13:30-15:00 | Managing emerging toxicities with novel treatments in myeloma <i>Springer Healthcare IME Independent, CME Accredited Symposium</i> |
| Day 1, Friday, May 7th | |
| 11:45-13:15 | B-cell maturation antigen (BCMA)-targeted agents: Emerging clinical considerations for a new pillar of therapy for the treatment of relapsed/refractory multiple myeloma (RRMM) <i>Industry Symposium</i> |
| 13:15-13:30 | Welcome by Congress chairs |
| 13:30-15:00 | Session 1: High risk disease biology |
| 13:30-13:45 | Disease risk scoring Hervé Avet-Loiseau, France |
| 13:45-14:00 | Genomics of high-risk myeloma Nikhil Munshi, USA |
| 14:00-14:15 | Drug resistance in Myeloma Keith Stewart, Canada |
| 14:15-15:00 | Round table debate Moderators: Gordon Cook, UK and Keith Stewart, Canada <i>Speakers and, Gordon Cook, UK, Gareth Morgan, USA</i> |
| 15:00-16:30 | Session 2: Immune deregulation in myeloma |
| 15:00-15:15 | Role of the microenvironment Irene Ghobrial, USA |
| 15:15-15:30 | Mechanisms of resistance to immunotherapy Niels van de Donk, Netherlands |
| 15:30-15:45 | Strategies to reverse immune deregulation in myeloma Paola Neri, Canada |
| 15:45-16:30 | Round table debate Moderator: Michael O'Dwyer, Ireland <i>Speakers and, Michael O'Dwyer, Ireland, Bertrand Arnulf, France, Marc Raab, Germany</i> |
| 16:30-18:00 | Close combat: bringing the immune system in to defeat multiple myeloma <i>Industry Symposium</i> |
| 18:00-19:15 | Session 3: Plenary lectures |
| 18:00-18:25 | Therapy of AL amyloidosis: an update Giampaolo Merlini, Italy |
| 18:25-18:50 | Therapy of Waldenstrom macroglobulinemia Steve Treon, USA |
| 18:50-19:15 | Round table debate Moderators: Thierry Facon, France and Mohamad Mohty, France <i>Speakers and, Jorge Castillo, USA</i> |
| 19:15-20:45 | Should cure be the goal for multiple myeloma? <i>Non-profit Symposium</i> |



| Day 2, Saturday, May 8th | |
|--|---|
| 10:00-11:00 | Session 4: Snapshot talks (part 1) - Latest data |
| 10:00-10:10 | Latest data on HDAC inhibitors Enrique Ocio , Spain |
| 10:10-10:20 | Latest data on Targeting SLAMF7 Katia Weisel , Germany |
| 10:20-10:30 | Latest data on targeting Bcl2 inhibitors Cyrille Touzeau , France |
| 10:30-10:45 | Latest data on biphosphonates Evangelos Terpos , Greece |
| 10:45-10:55 | Latest data on antibody drug conjugates Suzanne Trudel , Canada |
| 10:55-11:05 | Latest data in extra-medullary disease Artur Jurczynszyn , Poland |
| 11:05-12:20 | Session 5: Snapshot talks (part 2) - Clinical trials updates |
| 11:05-11:15 | IFM 2009 Aurore Perrot , France |
| 11:15-11:25 | Carfilzomib, lenalidomide, and dexamethasone plus transplant Andrzej Jakubowiak , USA |
| 11:25-11:35 | GRIFFIN Jonathan Kaufman , USA |
| 11:35-11:45 | MASTER Luciano Costa , USA |
| 11:45-11:55 | IKEMA Tom Martin , USA |
| 11:55-12:05 | CANDOR Saad Usmani , USA |
| 12:05-12:30 | Q&A Moderators: Arnon Nagler and Evangelos Terpos , Greece |
| 12:30-13:45 | <i>Cellular therapies: perspectives for practice</i> <i>Industry Symposium</i> |
| 13:45-15:00 | Session 6: Therapy of young patients |
| 13:45-14:00 | The optimal induction regimen Philippe Moreau , France |
| 14:00-14:15 | Role of consolidation (including double auto-transplant) Michele Cavo , Italy |
| 14:15-14:30 | Maintenance approaches post-transplant Francesca Gay , Italy |
| 14:30-15:00 | Round table debate Moderators: Mohamad Mohty , France and Philippe Moreau , France <i>Speakers and</i> , Peter Sonneveld , Netherlands, Joan Blade , Spain, Muzaffar Qazilbash , USA |



| | |
|--------------------|--|
| 15:00-16:15 | Session 7: Therapy of elderly patients |
| 15:00-15:15 | IMiD-based approaches Thierry Facon , France |
| 15:15-15:30 | Management of elderly myeloma: PLS based approaches Marivi Mateos , Spain |
| 15:30-15:45 | Personalized treatment of the elderly Sonja Zweegman , Netherlands |
| 15:45-16:15 | Round table debate Moderators: Meral Beksac , Turkey and Mohamad Mohty , France <i>Speakers and</i> , Alessandra Larocca , Italy, Meral Beksac , Turkey |
| 16:15-17:45 | <i>Out of the Trial and into the Real World: Closing the Gap in RRMM Industry Symposium</i> |
| 17:45-18:45 | Session 8: Therapy of smoldering myeloma – a debate |
| 17:45-18:00 | Pro S. Vincent Rajkumar , USA |
| 18:00-18:15 | Con Xavier Leleu , France |
| 18:15-18:45 | Round table debate Moderator: Arnon Nagler , Israel <i>Speakers and</i> , Shaji Kumar , USA, Aurore Perrot , France, Rafat Abonour , USA |
| 18:45-20:00 | Session 9: Plenary lectures |
| 18:45-19:10 | MRD-based therapy: hope, hype, or reality? Jesus San Miguel , Spain |
| 19:10-19:35 | How to extend survival at relapse? Meletios Dimopoulos , Greece |
| 19:35-20:00 | Round table debate Moderator: Mohamad Mohty , France <i>Speakers and</i> , Jean-Luc Harousseau , France, Nizar Bahlis , Canada, Kwee Yong , UK, Saad Usmani , USA |
| 20:00-21:00 | <i>Measurable Residual Disease in Multiple Myeloma: A Real-World Experience Perspective Industry Symposium</i> |

| Day 3, Sunday, May 9th | |
|--|---|
| 09:55-11:00 | ORAL PRESENTATIONS |
| | <p>AN ANALYSIS OF CYTOKINE RELEASE SYNDROME (CRS) IN THE KARMMA STUDY OF IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) FOR THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) Ibrahim Yakoub-Agha, France</p> <p>ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY AGENT AND/OR A PROTEASOME INHIBITOR (PI) — UPDATED EFFICACY AND SAFETY Enrique Ocio, Spain</p> <p>ASSOCIATION OF REDUCED ABSOLUTE iFLC and dFLC WITH PROLONGED MAJOR ORGAN DETERIORATION PROGRESSION-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS RECEIVING VCD WITH OR WITHOUT DARATUMUMAB: RESULTS FROM ANDROMEDA Efstathios Kastritis, Greece</p> <p>IN-CLASS TRANSITION (iCT) FROM THE PARENTERAL PROTEASOME INHIBITOR BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED REAL-WORLD RESULTS FROM THE COMMUNITY-BASED UNITED STATES (US) MM-6 STUDY Roger Lyons, USA</p> <p>RESULTS FROM A PHASE I DOSE-ESCALATION STUDY INVESTIGATING CLINICAL ACTIVITY AND SAFETY OF CEVOSTAMAB (ANTI-FCRH5XCD3) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE*] Andrew Spencer, Australia</p> <p>SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Christine Chen, Canada</p> <p>SUMMARY OF POTENTIAL RISK FACTORS ASSOCIATED WITH COVID-19 IN PATIENTS WITH MULTIPLE MYELOMA: PRELIMINARY REPORT FROM THE NATIONAL COVID COHORT COLLABORATIVE (N3C) Amit Kumar Mitra, USA</p> |
| 11:00-12:20 | Session 10: Snapshot talks - Practical considerations |
| 11:00-11:10 | <p>Practical considerations when using anti-CD38 antibodies Torben Plesner, Denmark</p> |
| 11:10-11:20 | <p>Management of cardiovascular adverse events Inger Nijhof, Netherlands</p> |
| 11:20-11:30 | <p>MRD monitoring: when, how and in which patient? Bruno Paiva, Spain</p> |
| 11:30-11:40 | <p>MGUS diagnosis: a step by step approach Graham Jackson, UK</p> |
| 11:40-11:50 | <p>Imaging: the essential work-up Elena Zamagni, Italy</p> |
| 11:50-12:00 | <p>COVID-19 vaccination in myeloma Heinz Ludwig, Austria</p> |
| 12:00-12:20 | <p>Q&A Moderators: Graham Jackson, UK and Heinz Ludwig, Austria</p> |
| 12:20-13:30 | <p><i>Managing multiple myeloma at first relapse: Emerging treatment paradigms</i> <i>Industry symposium</i></p> |



| | |
|--------------------|--|
| 13:30-14:30 | Session 11: Bispecific antibodies forum |
| 13:30-13:45 | The case for BCMA as a target Alfred Garfall, USA |
| 13:45-14:00 | The case for non-BCMA targets Ajai Chari, USA |
| 14:00-14:30 | Round table debate Moderators: Luciano Costa, USA and Mohamad Mohty, France <i>Speakers and, Adam Cohen, USA, Hermann Einsele, Germany, Luciano Costa, USA</i> |
| 14:30-15:30 | Session 12: CAR-T cells forum |
| 14:30-14:45 | The case for Ide-Cel Noopur Raje, USA |
| 14:45-15:00 | The case for Cilta-Cel Deepu Madduri, USA |
| 15:00-15:30 | Round table debate Moderators: Arnon Nagler, Israel and Mohamad Mohty, France <i>Speakers and, Nina Shah, USA, Arnon Nagler, Israel, Salomon Manier, France, Caitlin Costello, USA</i> |
| 15:30-16:30 | Session 13: Novel drugs forum |
| 15:30-15:40 | Melflufen-based combinations Paul Richardson, USA |
| 15:40-15:50 | Iberdomide-based combinations Sagar Lonial, USA |
| 15:50-16:00 | XPO inhibitors Mohamad Mohty, France |
| 16:00-16:10 | Venetoclax: for which patients? Rafael Fonseca, USA |
| 16:10-16:30 | Round table debate Moderator: Rafael Fonseca, USA Speakers |
| 16:30-17:30 | <i>Uncharted territories: the expanding RRMM treatment landscape Industry Symposium</i> |
| 17:30-18:00 | Session 14: Plenary lecture |
| 17:30-18:00 | Multiple myeloma in 2025: the next steps? Kenneth Anderson, USA |
| 18:00-18:30 | Awards Ceremony |